Agmatine is not a good candidate as endogenous ligand for imidazoline sites of pancreatic B cells and vascular bed

European Journal of Pharmacology

Volumn 308, Issue 3, 1996, Pages 301-304

  Berdeu, Daniel ^a   Puech, Raymond ^b   Loubatières Mariani, Marie Madeleine ^a   Bertrand, Gyslaine ^b  

^a Laboratoire de Biochimie Genetique   (France)

^b INSERM   (France)

Author keywords

Agmatine; Efaroxan; Imidazoline receptor; Insulin secretion; Pancreas, rat; Vessel

Indexed keywords

AGMATINE; EFAROXAN; GLUCOSE; IMIDAZOLINE RECEPTOR; IMIDAZOLINE RECEPTOR AGONIST; INSULIN; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; INSULIN RELEASE; MALE; NONHUMAN; PANCREAS BLOOD FLOW; PANCREAS ISLET BETA CELL; PANCREAS PERFUSION; PRIORITY JOURNAL; RAT; VASOCONSTRICTION;

EID: 0030601244     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/0014-2999(96)00329-9     Document Type: Article

References (13)

1. Alberti, K., H. Woods and M. Whalley, 1973, Mechanism of action of the monoguanidine hypoglycaemic agents, galegine and agmatine, Eur. J. Clin. Invest. 3, 208 (Abstract).
2. Berdeu, D., R. Gross, G. Ribes, M.M. Loubatières-Mariani and G. Bertrand, 1994, Effects of imidazolines and derivatives on insulin secretion and vascular resistance in perfused rat pancreas, Eur. J. Pharmacol. 254, 119.
3. Berdeu, D., R. Gross, R. Puech, M.M. Loubatières-Mariani and G. Bertrand, 1995, Evidence for different imidazoline sites on pancreatic B cells and vascular bed in rat, Eur. J. Pharmacol. 275, 91.
4. +ATP channels in insulin-secreting cells, Eur. J. Pharmacol. 204, 41.
5. Glavin, G.B., M.A. Carlisle and D.D. Smyth, 1995, Agmatine, an endogenous imidazoline receptor agonist, increases gastric secretion and worsens experimental gastric mucosal injury in rats, J. Pharmacol. Exp. Ther. 274, 741.
6. + channels in pancreatic β-cells, Br. J. Pharmacol. 107, 8.
7. Li, G., S. Regunathan, C.J. Barrow, J. Eshraghi, R. Cooper and D.J. Reis, 1994, Agmatine: an endogenous clonidine-displacing substance in the brain, Science 263, 966.
8. Loubatières, A.L., M.M. Mariani, H. De Malbosc, G. Ribes and J. Chapal, 1969, Étude expérimentale d'un nouveau sulfamide hypoglycémiant particulièrement actif, le HB 419 ou glibenclamide. I. Action bêtacytotrope et insulino-sécrétrice, Diabetologia 9, 439.
9. Michel, M.C. and P. Ernsberger, 1992, Keeping an eye on the I site: imidazoline-preferring receptors, Trends Pharmacol. Sci. 13, 369.
10. 2-imidazoline binding sites, Naunyn-Schmiedeberg's Arch. Pharmacol. 351, 507.
11. 2-adrenoceptors, Naunyn-Schmiedeberg's Arch. Pharmacol. 351, 10.
12. Schulz, A. and A. Hasselblatt, 1989, An insulin-releasing property of imidazoline derivatives is not limited to compounds that block α-adrenoceptors, Naunyn-Schmiedeberg's Arch. Pharmacol. 340, 321.
13. Sener, A., P. Lebrun, F. Blachier and W.J. Malaisse, 1989, Stimulus-secretion coupling of arginine-induced insulin release, Biochem. Pharmacol. 38, 327.